AMANTA HEALTHCARE LIMITED AMANTA NSEPHARMA
Company Overview
Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin America, the United Kingdom, and internationally. The company manufactures its products in three product group segments Large Volume Parenteral, Nipple Head (Single Port), SteriPort (Two Ports), and Small Volume Parenteral. Additionally, it manufactures medical devices and fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products, such as irrigation, first-aid solution, and eye lubricants in medical device segment. It also offers a wide range of closure systems, such as nipple head, twist-off, leur-lock, and screw types and container fill-volume ranging from 2ml to 1000 ml. Its markets its products through three strategic business units including national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. Amanta Healthcare Limited was formerly known as Marck Biosciences Limited and changed its name to Amanta Healthcare Limited in June 2014. Amanta Healthcare Limited was incorporated in 1994 and is headquartered in Ahmedabad, India.
Why Investors Should Care
Net profit has compounded at 268.3% per year over the last five years.
Recent Developments
- Mar 2026 Revenue of ₹287.68 Cr (+4.7% YoY); net profit ₹14.88 Cr.
- Trailing 12 Months Year-on-year growth — revenue +4.7%, earnings +41.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.8%, profit CAGR 268.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.76% |
| 1 Year: | 4.72% |
Compounded Profit Growth
| 5 Years: | 268.26% |
| 1 Year: | 41.66% |
Stock Price Performance
| 1 Year: | +35.99% |
| 6 Months: | +92.64% |
| 3 Months: | +43.24% |
| 1 Month: | +14.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.15 · Neutral
P/E of 44.81 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 268.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMANTA AMANTA HEALTHCARE LIMITED NSEPHARMA | 194.03 | 44.81 | ₹753.41 Cr | 0.00% | 10.04% | 6.75% | 3.76% | 268.26% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 67.81 Cr | 72.06 Cr | 70.89 Cr | 74.49 Cr | 76.99 Cr |
| Cost of Revenue | 21.60 Cr | 24.47 Cr | 23.37 Cr | 26.29 Cr | 28.87 Cr |
| Gross Profit | 46.21 Cr | 47.59 Cr | 47.52 Cr | 48.20 Cr | 48.13 Cr |
| Operating Expenses | 35.65 Cr | 33.32 Cr | 37.53 Cr | 37.51 Cr | 37.93 Cr |
| Operating Income | 10.56 Cr | 14.27 Cr | 9.99 Cr | 10.69 Cr | 10.20 Cr |
| EBITDA | 15.93 Cr | 19.13 Cr | 12.09 Cr | 16.04 Cr | 16.61 Cr |
| Interest Expense | 5.90 Cr | 6.28 Cr | 5.15 Cr | 5.06 Cr | 4.25 Cr |
| Pretax Income | 5.53 Cr | 8.15 Cr | 2.28 Cr | 6.30 Cr | 7.62 Cr |
| Tax Provision | 1.25 Cr | 2.19 Cr | 1.07 Cr | 1.67 Cr | 2.09 Cr |
| Net Income | 4.28 Cr | 5.96 Cr | 1.21 Cr | 4.63 Cr | 5.53 Cr |
| Diluted EPS | 1.10 | 1.53 | 0.35 | 1.35 | 1.61 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 257.53 Cr | 278.44 Cr | 274.71 Cr | 287.68 Cr |
| Cost of Revenue | - | 105.51 Cr | 109.67 Cr | 94.06 Cr | 96.65 Cr |
| Gross Profit | - | 152.02 Cr | 168.77 Cr | 180.65 Cr | 191.03 Cr |
| Operating Expenses | - | 117.16 Cr | 130.46 Cr | 139.38 Cr | 149.90 Cr |
| Operating Income | - | 34.86 Cr | 38.31 Cr | 41.27 Cr | 41.13 Cr |
| EBITDA | - | 55.42 Cr | 57.52 Cr | 61.05 Cr | 60.60 Cr |
| Interest Expense | - | 34.38 Cr | 32.40 Cr | 27.95 Cr | 20.75 Cr |
| Pretax Income | - | 2.69 Cr | 5.39 Cr | 14.71 Cr | 21.12 Cr |
| Tax Provision | - | 4.80 Cr | 1.76 Cr | 4.21 Cr | 6.25 Cr |
| Net Income | - | -2.11 Cr | 3.63 Cr | 10.50 Cr | 14.88 Cr |
| Diluted EPS | - | -0.54 | 0.94 | 2.70 | 4.33 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 374.06 Cr | 352.12 Cr | 381.76 Cr | 557.98 Cr |
| Current Assets | - | 131.01 Cr | 117.89 Cr | 137.92 Cr | 238.53 Cr |
| Cash & Equivalents | - | 11.11 L | 1.54 Cr | 22.06 L | 81.01 Cr |
| Inventory | - | 68.92 Cr | 59.45 Cr | 72.98 Cr | 82.71 Cr |
| Receivables | - | 53.58 Cr | 48.17 Cr | 50.08 Cr | 43.02 Cr |
| Total Liabilities | - | 311.18 Cr | 285.83 Cr | 285.37 Cr | 337.77 Cr |
| Current Liabilities | - | 97.13 Cr | 101.66 Cr | 115.08 Cr | 141.06 Cr |
| Long Term Debt | - | 164.83 Cr | 138.01 Cr | 121.02 Cr | 161.97 Cr |
| Total Debt | - | 214.00 Cr | 200.08 Cr | 192.60 Cr | 244.44 Cr |
| Total Equity | - | 62.88 Cr | 66.29 Cr | 96.39 Cr | 220.21 Cr |
| Shares Outstanding | - | 3.88 Cr | 3.88 Cr | 3.88 Cr | 3.88 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 42.58 Cr | 58.07 Cr | 46.62 Cr | 48.45 Cr |
| Investing Cash Flow | - | -6.53 Cr | -10.32 Cr | -24.47 Cr | -93.61 Cr |
| Financing Cash Flow | - | -42.32 Cr | -46.32 Cr | -23.47 Cr | 125.95 Cr |
| Capital Expenditure | - | -6.29 Cr | -13.41 Cr | -20.77 Cr | -80.19 Cr |
| Free Cash Flow | - | 36.29 Cr | 44.66 Cr | 25.85 Cr | -31.74 Cr |
| Net Change in Cash | - | -6.27 Cr | 1.43 Cr | -1.32 Cr | 80.79 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 59.0% | 60.6% | 65.8% | 66.4% |
| Operating Margin % | - | 13.5% | 13.8% | 15.0% | 14.3% |
| Net Margin % | - | -0.8% | 1.3% | 3.8% | 5.2% |
| ROE % | - | -3.4% | 5.5% | 10.9% | 6.8% |
| ROCE % | - | 12.6% | 15.3% | 15.5% | 9.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMANTA
AMANTA Stock Price and Chart — NSE:AMANTA - TradingView
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5lV2VCSDJIdzdKNXJXdUN2UXQ3cTNTWHhlNDJ3RTY3S1Noem9KemJfZU54SWU0Z0JCMnhFTS1pM3pfTnVZRldxN0tZQ19zXzNCSFdaS2pkeWR4SEk?oc=5" target="_blank">AMANTA Stock Price and Chart — NSE:AMANTA</a…
Amanta Healthcare Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPY29MRkxyVHRsU3B3ZVh2T0pxT1g3b3RMWlRVZkRLSVdrYXpsOVhsSzhYcVFMVGpFYmF0eWZwT3pDTEFjVFNSTXZBNFNIN0RNakhNWmJjRms3QThQU2RCaTJNUTJCWGx3RmpWVEZtYk8zZDBsdVZEQi1PMkJzNlNpbm03Z2M3aWhqZGl3?o…
Amanta Healthcare Co-Promoter Acquires 63 Lakh Shares Representing 16.3% Stake Via Open Market - Sahi
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNdk9vNVJHcjBYUFlia1c4cTRCNF9uZnhyeEszcy02ZmhlMUJmeDhHYzJKSVB0cnctVHprZnlfMWRSY0Y1VXVjY0lyVTRBRGFhS1BqdENlQV9KVmNmZ0w4R2gzeW94dWFTN0lxQ2I2NUotY0J3UDcwM0syY0hadk5scHV3bzdnLVE4R2k4N3…
Amanta Healthcare shares web-link for FY26 annual report and AGM notice - scanx.trade
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOcWNsT1poU2M1XzNDcUEyczVFMFhfYXEwNkljb2llTGlvaWRHMy16TVIzRWJIMkUzaE5MNldEU0Fralp1U2NvYzBVdlpmZXdnemQ1Z2RkVVRnU2ZvMjBhMzUtYXNtM2N2ckRGMjhkcWs2SkJpeDhfeWRXM1FNM1ZRNWs5SktLUjYwVzg0dH…
Amanta Healthcare Bounces from Support: Stock Gains 2.69% on NSE - Profitability Factor - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQY2xsNUdTWmotNGNSNEZwWlJRUmozZmt3bmRwOGhtdk5fbnBlWjAwM2tKWWhlN3NwY3c5d1dtR1dveTBpZUY4cjhLUXc2TmxQN2RTXzZTbkxJSDdpVVNGVjF1YzhTTjRYMzBUREt2SG1BcjF6SWxqdUZCUDFMcVJBaUY4VERPTWVJcFBKZW…
Amanta Health Standalone March 2026 Net Sales at Rs 76.99 crore, up 6.84% Y-o-Y - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQblh0VUp5VEtRVUJQQVFmMUYxVXcta1dscnNMWi1seTFJNEM2a0cwX001WnBzR21fOGJwZEV5WmMzVGtTR1JYbG9uZkxPbXo3ekx4R1dGdy1lRU9KeHlNdEFaZjE2QzVuYXMxZlBFN1BNa2JGMTNkNVFnSFc1d3hpZWhHTDFvZnRPQ1R3Ym…
AMANTA — Frequently Asked Questions
What is the current share price of AMANTA HEALTHCARE LIMITED (AMANTA)?
As of 2026-09-08 04:53 IST, AMANTA HEALTHCARE LIMITED (AMANTA) trades at ₹194.03 on NSE. Its 52-week range is ₹95.03 to ₹205.17.
What is the market capitalisation of AMANTA?
AMANTA HEALTHCARE LIMITED (AMANTA) has a market capitalisation of ₹753.41 Cr on NSE.
What is the P/E ratio of AMANTA?
AMANTA trades at a trailing price-to-earnings (P/E) ratio of 44.81. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.59.
What is the return on equity (ROE) of AMANTA?
AMANTA has a return on equity (ROE) of 6.75%. Its return on capital employed (ROCE) is 10.04%.
Is AMANTA a good stock to buy?
This page provides a data-driven analysis of AMANTA HEALTHCARE LIMITED (AMANTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.